#1 Clinical Trials Search in Europe

Efgartigimod Alfa

Efgartigimod Alfa, a promising drug in the field of autoimmune disorders, is currently being studied in various clinical trials. These trials aim to evaluate its safety and effectiveness in treating conditions such as Myasthenia Gravis, Guillain-Barré Syndrome, Optic Neuritis, and Neuromyelitis Optica Spectrum Disorders. The drug works by reducing harmful antibodies in the body, potentially offering new hope for patients with these challenging conditions.

Table of Contents

What is Efgartigimod Alfa?

Efgartigimod Alfa is a new medication being studied for the treatment of various autoimmune disorders. It’s also known by the brand name Vyvgart or Vyvgart Hytrulo[1]. This drug is designed to reduce the levels of certain antibodies in the body that are responsible for causing autoimmune diseases[2].

How Does Efgartigimod Alfa Work?

Efgartigimod Alfa works by targeting a specific receptor in the body called the neonatal Fc receptor (FcRn). This receptor plays a crucial role in maintaining high levels of antibodies, specifically immunoglobulin G (IgG), in the bloodstream. By blocking the FcRn, Efgartigimod Alfa causes these antibodies to break down more quickly, reducing their levels in the body[1].

In autoimmune diseases, the body’s immune system mistakenly attacks its own tissues. By lowering the levels of these harmful antibodies, Efgartigimod Alfa may help to reduce the severity of autoimmune symptoms and improve patient outcomes[2].

What Conditions Does Efgartigimod Alfa Treat?

Efgartigimod Alfa is being studied for several autoimmune conditions, including:

  • Myasthenia Gravis: A condition that causes muscle weakness and fatigue[2].
  • Guillain-Barré Syndrome (GBS): A rare disorder where the body’s immune system attacks the nerves, causing weakness and tingling in the extremities[1].
  • Neuromyelitis Optica Spectrum Disorder (NMOSD): An autoimmune disease that primarily affects the optic nerves and spinal cord[3].
  • Optic Neuritis: Inflammation of the optic nerve that can cause vision loss[4].

How is Efgartigimod Alfa Administered?

The administration of Efgartigimod Alfa can vary depending on the condition being treated and the specific clinical trial. However, it is generally given in the following ways:

  • Intravenous (IV) infusion: The medication is given directly into a vein over a period of time, usually about 1-2 hours[2].
  • Subcutaneous injection: The medication is injected under the skin[4].

The dosage and frequency of administration can vary. For example, in some trials, it’s given weekly for a certain number of weeks, while in others, it might be given less frequently[2][4].

Current Clinical Trials

Efgartigimod Alfa is currently being studied in several clinical trials for different conditions:

  • Myasthenia Gravis and Thymoma: A study is evaluating the safety and effectiveness of Efgartigimod Alfa when used before and after surgery (thymectomy) in patients with both myasthenia gravis and thymoma (a type of tumor)[2].
  • Acute Optic Neuritis: Researchers are investigating whether Efgartigimod Alfa can improve vision outcomes in patients with sudden inflammation of the optic nerve[4].
  • Guillain-Barré Syndrome: A trial is comparing Efgartigimod Alfa to the standard treatment (intravenous immunoglobulin) for GBS[1].
  • Neuromyelitis Optica Spectrum Disorder: A study is looking at whether Efgartigimod Alfa can help treat acute attacks in patients with NMOSD[3].

Potential Side Effects and Safety

As with any medication, Efgartigimod Alfa may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some trials are specifically monitoring for:

  • Changes in vital signs
  • Abnormalities in blood tests
  • Changes in heart rhythm (as seen on an electrocardiogram)
  • Any other adverse events that may occur during treatment[3]

It’s important to note that the safety profile of Efgartigimod Alfa is still being established through these clinical trials. Patients participating in these studies are closely monitored for any potential side effects or safety concerns[1][4].

Condition Trial Phase Key Outcomes Administration
Myasthenia Gravis with Thymoma Not specified Change in ADL score, QMG score, MGC score IV, 10 mg/kg on Days 1, 8, 15, 22
Acute Optic Neuritis Pilot Changes in visual acuity, recruitment rate, study adherence Subcutaneous, 2,016 mg on Day 0 and 3
Guillain-Barré Syndrome Phase 2 GBS Disability Scale, adverse events, biomarker levels IV, 20 mg/kg on days 1 and 5
Neuromyelitis Optica Spectrum Disorders Phase 2 Change in EDSS score, visual outcomes, serum antibody levels IV, 10 mg/kg on Weeks 0, 1, 2, 3

FAQ

  • What is Efgartigimod Alfa and how does it work? Efgartigimod Alfa is an antibody fragment that targets the neonatal Fc receptor (FcRn). It works by blocking FcRn, which leads to a faster breakdown of harmful antibodies in the body. This mechanism can potentially help in treating various autoimmune disorders.
  • What conditions are being studied with Efgartigimod Alfa in these clinical trials? The clinical trials are investigating Efgartigimod Alfa for several conditions, including Myasthenia Gravis, Guillain-Barré Syndrome, Optic Neuritis, and Neuromyelitis Optica Spectrum Disorders.
  • How is Efgartigimod Alfa administered in these trials? The administration of Efgartigimod Alfa varies depending on the trial. It may be given intravenously (through a vein) or subcutaneously (under the skin). The dosage and frequency also differ based on the specific study and condition being treated.
  • What are the primary outcomes being measured in these trials? The primary outcomes vary by trial but generally include measures of disease activity and severity, such as changes in disability scales, visual acuity, and quality of life scores. Safety assessments, including the number and seriousness of adverse events, are also key outcomes.
  • How long do these clinical trials typically last? The duration of the trials varies, but many extend for several months to a year or more. Some trials include follow-up periods of up to 48 weeks to assess long-term outcomes and safety.

Ongoing Clinical Trials on Efgartigimod Alfa

  • A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Greece Italy The Netherlands Poland +1

  • Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

    Recruiting

    1 1
    Investigated drugs:
    France Germany Hungary Italy Lithuania Poland +2

  • Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

    Recruiting

    1 1
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Study on the Effectiveness and Safety of Efgartigimod IV for Adults with Primary Immune Thrombocytopenia

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Bulgaria Croatia Czechia France Germany +8

  • Study on Efgartigimod for Early Treatment in Patients with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +3

  • Study on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Cyprus Czechia Denmark +13

  • Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Recruiting

    1 1
    Investigated drugs:
    Austria Belgium Bulgaria Denmark France Germany +5

Glossary

  • Efgartigimod Alfa: An antibody fragment that targets the neonatal Fc receptor (FcRn), leading to a reduction in harmful antibodies in the body. It's being studied as a potential treatment for various autoimmune disorders.
  • Myasthenia Gravis: An autoimmune disorder causing muscle weakness and fatigue, often affecting the eyes and face, swallowing, and breathing.
  • Guillain-Barré Syndrome: A rare disorder where the body's immune system attacks the nerves, causing weakness and tingling that can progress to paralysis.
  • Optic Neuritis: Inflammation of the optic nerve that can cause sudden vision loss, often associated with multiple sclerosis or other autoimmune conditions.
  • Neuromyelitis Optica Spectrum Disorders (NMOSD): A group of autoimmune disorders primarily affecting the optic nerves and spinal cord, causing vision loss and muscle weakness.
  • FcRn (neonatal Fc receptor): A protein that helps protect certain antibodies from being broken down, extending their lifespan in the body.
  • Intravenous (IV): Administration of a substance directly into a vein.
  • Subcutaneous: Administration of a substance under the skin.
  • Thymoma: A tumor originating from the thymus gland, often associated with myasthenia gravis.
  • Aquaporin-4 (AQP4): A water channel protein targeted by antibodies in some cases of neuromyelitis optica spectrum disorders.
  • EDSS (Expanded Disability Status Scale): A method of quantifying disability in multiple sclerosis and other neurological conditions.
  • Neurofilament Light Chain (NfL): A protein released when neurons are damaged, used as a biomarker for neurological diseases.
  • Forced Vital Capacity (FVC): A measure of lung function, indicating the maximum amount of air a person can forcibly exhale.

References

  1. https://clinicaltrials.gov/study/NCT05701189
  2. https://clinicaltrials.gov/study/NCT06221501
  3. https://clinicaltrials.gov/study/NCT06497374
  4. https://clinicaltrials.gov/study/NCT06453694